Improving Access to Medicines – Pharmaceutical Benefits Scheme – price amendments

Since the 2016–17 Mid-Year Economic and Fiscal Outlook, the Australian Government has made minor amendments to the price of several medicines currently listed on the Pharmaceutical Benefits Scheme (PBS). These variations involved minor price changes in both directions.

Page last updated: 09 May 2017

PDF version: Improving Access to Medicines – Pharmaceutical Benefits Scheme – price amendments (PDF 112 KB)

Concessional patients will pay no more than the current co-payment of $6.30. General patients will pay no more than $38.80.

Why is this important?

These price amendments ensure some crucial medicines, like medicines to treat auto-immune conditions, remain on the PBS at a price that is cost-effective for the Government and consumers.

The continued availability of these important medicines on the PBS also helps prevent patients from moving to more expensive PBS-listed medicines or non-PBS subsidised expensive treatment options.

These changes have been updated on the PBS website (www.pbs.gov.au).

Who will benefit?

The price changes will ensure patients continue to have subsidised access to essential PBS medicines, which remain cost-effective to the Government.

How much will this cost?

This measure will save $270.2 million from 2016–17 to 2020–21.

In this section